Melatonin for sleep linked to 90% higher risk of heart failure, study finds

New research from the American Heart Association indicates that long-term melatonin use (over one year) is associated with a significantly increased risk of heart failure, hospitalization, and all-cause mortality, with a study of over 130,000 adults showing a 90% higher heart failure risk. This finding is particularly notable given melatonin's status as an unregulated over-the-counter supplement, where potency and purity can vary widely. While experts emphasize correlation over causation, the study challenges the perception of 'natural' supplements as risk-free and suggests a need for reevaluating chronic use, potentially influencing consumer behavior and future regulatory scrutiny within the supplement market.

Analysis

New research presented by the American Heart Association indicates a significant health risk associated with long-term melatonin use. A five-year study of over 130,000 adults found that individuals using melatonin for a year or more faced a 90% higher risk of heart failure and were nearly twice as likely to die from any cause. Hospitalization for heart failure was 3.5 times more likely among long-term users, highlighting substantial adverse outcomes.

This finding is particularly salient given melatonin's status as an unregulated over-the-counter supplement in the U.S., where potency and purity can vary widely. The study challenges the common perception that "natural" supplements are inherently risk-free, potentially shifting consumer behavior and increasing scrutiny on the broader dietary supplement market.

While experts emphasize that the study establishes correlation, not direct causation, and acknowledges potential confounding factors like chronic insomnia, the preliminary results underscore a growing concern. Further research is needed to differentiate whether melatonin directly contributes to cardiac issues or merely signals underlying health problems. This could prompt reevaluation of chronic melatonin use by healthcare professionals and consumers.

Key Decisions for Investors

• Investors should monitor potential shifts in consumer demand for over-the-counter sleep aids, particularly melatonin, as public awareness of these health risks increases.
• Companies operating in the dietary supplement sector, especially those with significant melatonin product lines, may face increased regulatory scrutiny or calls for more stringent product testing and labeling.
• Consider evaluating the competitive landscape for alternative, potentially regulated, sleep solutions or pharmaceutical sleep aids, which could see increased market interest.
• Assess the long-term implications for companies whose revenue is heavily reliant on unregulated supplements, as this research could be a precursor to broader industry changes.